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Abstract
Preliminary in vitro and in vivo studies with valproic acid (VPA) in cell lines and patients with spinal muscular atrophy (SMA)
demonstrate increased expression of SMN, supporting the possibility of therapeutic benefit. We performed an open label
trial of VPA in 42 subjects with SMA to assess safety and explore potential outcome measures to help guide design of future
controlled clinical trials. Subjects included 2 SMA type I ages 2–3 years, 29 SMA type II ages 2–14 years and 11 type III ages
2–31 years, recruited from a natural history study. VPA was well-tolerated and without evident hepatotoxicity. Carnitine
depletion was frequent and temporally associated with increased weakness in two subjects. Exploratory outcome measures
included assessment of gross motor function via the modified Hammersmith Functional Motor Scale (MHFMS),
electrophysiologic measures of innervation including maximum ulnar compound muscle action potential (CMAP)
amplitudes and motor unit number estimation (MUNE), body composition and bone density via dual-energy X-ray
absorptiometry (DEXA), and quantitative blood SMN mRNA levels. Clear decline in motor function occurred in several
subjects in association with weight gain; mean fat mass increased without a corresponding increase in lean mass. We
observed an increased mean score on the MHFMS scale in 27 subjects with SMA type II (p#0.001); however, significant
improvement was almost entirely restricted to participants ,5 years of age. Full length SMN levels were unchanged and
D7SMN levels were significantly reduced for 2 of 3 treatment visits. In contrast, bone mineral density (p#0.0036) and
maximum ulnar CMAP scores (p#0.0001) increased significantly.
Conclusions: While VPA appears safe and well-tolerated in this initial pilot trial, these data suggest that weight gain and
carnitine depletion are likely to be significant confounding factors in clinical trials. This study highlights potential strengths
and limitations of various candidate outcome measures and underscores the need for additional controlled clinical trials
with VPA targeting more restricted cohorts of subjects.
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Introduction
Spinal muscular atrophy (SMA) is the most common inherited
motor neuron disease, and a leading cause of infant and childhood
mortality [1,2]. With an incidence of 1 in 10,000 births, it is an
autosomal recessive disorder associated with severe neuromuscular
weakness and premature death in the majority of patients [3–6].
More than 96% of affected individuals demonstrate a homozygous
deletion/mutation involving exon 7 in SMN1 (survival motor
neuron 1), resulting in the biochemical deficiency of the SMN
protein, part of a complex that functions in the assembly of small
nuclear ribonucleoprotein particles (snRNP) [7,8]. A genomic
duplication at this locus has resulted in a nearly identical gene,
SMN2 (survival motor neuron 2). SMN2 differs from SMN1 by a
nucleotide substitution that promotes exon 7 exclusion. Conse-
quently, SMN2 produces a fraction of the identical full length
protein. Phenotypic variation in SMA correlates with the number
of SMN2 gene copies and the level of SMN protein in cells [9–15].
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clinical types including the most common severe infantile form
(SMA type I), non-ambulatory variants of intermediate severity
(SMA type II), and ambulatory variants (SMA types III, IV). The
majority of subjects develop symptoms in infancy or early
childhood.
An opportunity for therapeutic intervention has arisen from the
discovery of small molecule compounds which target SMN2 gene
copies present in all SMA patients to produce increased amounts
of full-length SMN protein. Several compounds demonstrated to
up-regulate SMN expression in SMA patient-derived cell lines,
including valproic acid (VPA), sodium phenylbutyrate (NaPB) and
hydroxyurea (HU), have been in clinical use for decades. These
histone deacetylase (HDAC) inhibitors variably increase expres-
sion of many genes, including the SMN gene [16–20]. Preliminary
in vivo data in human subjects supports up-regulation of SMN by
both VPA and NaPB [21,22]. VPA up-regulates SMN2 expression
at the promoter via inhibition of HDAC2, and both VPA and HU
appear to alter splicing to increase full-length SMN protein
[20,23]. VPA has demonstrated neuroprotective properties on
glutamate-induced excitotoxicity via up-regulation of alpha-
synuclein and increases neurite outgrowth in vitro[24,25]. Both
VPA and NaPB have been reported to increase survival in ALS
animal models [26,27]. More recently, VPA administration in an
SMA mouse model resulted in apparent improved motor function,
larger evoked motor potentials, less degeneration of spinal motor
neurons and improved neuromuscular junction innervation in
treated animals compared to age-matched controls [28,29].
Finally, two small open label trials of VPA in human subjects
have reported modest strength or functional benefit in a subset of
those patients [30,31]. Such observations support the potential
benefit of small molecule therapeutics not only for SMA, but for
other forms of motor neuron disease, such as ALS. This
preliminary in vivo and in vitro evidence encouraged us to
proceed with an open label study of VPA in SMA patients as a first
step towards more formal efficacy studies. Our primary objectives
were to determine the safety of VPA in SMA patients and to assess
the utility of a number of exploratory outcome measures for future
clinical trials.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Study population
Subjects participating in a natural history study at the
University of Utah were recruited for an open label study of
VPA (Clinicaltrials.gov ID NCT00374075). All subjects at least 2
years of age receiving ,16 hours/day ventilator support were
invited to participate. Fifty-eight subjects were enrolled in the
natural history study. At the start of VPA study enrollment,
thirteen type I subjects were deceased, required full-time
mechanical ventilation, or were less than 2 years of age. Two
subjects were excluded for prior noncompliance with natural
history study visits. Two subjects declined due to the burden of
study visits. Three additional subjects declined due to perceived
risks. Enrollment was then opened in the order of calls received to
recruit 4 additional subjects. Type I subjects were not specifically
excluded but enrollment was discontinued following recruitment
of 40 type II and type III subjects. Two subjects had a severe
phenotype (SMA type I ages 2–3 years), 29 subjects had an
intermediate phenotype (SMA type II ages 2–14 years) and 11 had
a mild phenotype (SMA type III ages 2–31 years). Additional
details of baseline study population characteristics are shown in
Tables S1 and S2. The progress of all participants through the trial
is diagrammed in Figure S1.
Consent and adverse event grading
Written informed consent (subjects $18 years), parental consent
(subjects ,18 years) and assent (subjects $7 years) were obtained
for all subjects. The study was approved by the University of Utah
Institutional Review Board and General Clinical Research Center
Advisory Committees. Adverse events were graded using Com-
mon Terminology Criteria for Adverse Events v3.0 (CTCAE
v3.0). An independent Data and Safety Monitoring Committee
provided oversight for the study.
Study design
Inclusion criteria were age $2 years and confirmed genetic
diagnosis of SMA. Exclusion criteria were ventilator support for
$16 hours or concomitant medications with known hepatotoxicity
or potential benefit in SMA. Each subject had to complete $2
natural history assessments within a 3–6 month period to qualify
for enrollment in the VPA trial. Treatment assessments were
performed at 3 (V1), 6 (V2) and 12 (V3) months. Divalproex
sodium coated particles (DepakoteH sprinkle capsules, 125 mg per
capsule) were administered in divided doses two to three times
daily sufficient to maintain overnight trough levels of 50–100 mg/
dL. Dosing was typical of that used in epilepsy patients (15–
50 mg/kg/day). Laboratory testing, which included a basic
chemistry profile, CBC with platelets, transaminases, carnitine
profile, amylase, lipase, and trough VPA levels, was performed at
baseline, 2–3 weeks following initiation, and at each treatment
visit.
Primary outcome measures were laboratory safety and adverse
event data. Exploratory outcome measures included change from
baseline assessments of motor function, pulmonary function
(subjects $5 years), degree of denervation via maximum ulnar
compound motor action potential (CMAP) and motor unit
number estimation (MUNE) values, dual-energy X-ray absorpti-
ometry (DEXA) of body composition and bone density and
quantitative assessment of SMN mRNA.
Gross motor function was assessed with the Modified Hammer-
smith Functional Motor Scale for SMA (MHFMS). This scale
contains the same 20 gross motor items as the original clinical
scale, but was modified for use in the research setting [32,33]. A
version of this scale has been successfully used in a multicenter trial
with SMA subjects [34]. Each item is scored from 0–2, with a
hierarchy of skills ranging from rolling to sitting to standing.
Unfortunately, this scale as it stands in its present form is
inadequate for testing subjects across the full range of SMA
phenotypes, due to significant floor and ceiling effects for subjects
with SMA types I and III, respectively (additional details available
at http://www.smaoutcomes.org). The degree of denervation in
the hand was estimated using maximum ulnar CMAP amplitude
and MUNE negative peak area values [12,35]. In children $5
years, pulmonary function testing (PFT) was performed in an
accredited pediatric laboratory, and included forced vital capacity
(FVC), forced expiratory volume in 1 second (FEV1), and
maximum expiratory and inspiratory pressures (MEP and MIP,
respectively). We analyzed absolute values rather than corrected
values due to concerns regarding accurate measurements of length
due to contractures in many subjects. Norland DEXA XR-36
software version 3.3.1 for small subjects was used to assess whole
body composition and bone mineral density and content.
Phase II Study of VPA in SMA
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[11]. Whole blood was drawn into PAXgene tubes at baseline and
each visit. Quantitative SMN mRNA levels were performed with
slight modifications to the prior protocol [36]. Assays were carried
out on a 7500 Real Time PCR system (Applied Biosystems). To
increase efficiency on this apparatus, full-length SMN was
amplified by primers 59-GCTTTGGGAAGTATGTTAATTT-
CATGGT-39 (exon 6) and 59-TGTGAGCACCTTCCTTC-
TTTTTGAT-39 (exon 7), and detected by the 59FAM-TC-
TGAAACCCATATAATAGCC-MGBNFQ-39 exon 6–7 junc-
tion probe. Delta-7 (D7) SMN was detected as published [36].
Human RPLPO (large ribosomal protein) and PGK1 (phospho-
glycerate kinase 1) were run as endogenous controls. Patients
missing baseline data or who had only one treatment visit were
excluded from this analysis. Results are reported as relative
amounts of full-length (fl) or D7SMN transcripts normalized
against the relative amount of RPLPO.
Statistical Analysis
The analysis of variance (ANOVA) test was used to evaluate the
differences between means for function tests. When a factor level is
empty and only two levels exists, ANOVA defaults to t-test. Linear
regression analysis was used to examine the relationship between
function parameters and genetic variables at baseline. The
dependent variables in the linear regressions were evaluated for
normality using the Shapiro-Wilk test and the paired t-test was
used to test change from baseline in follow-up. If the dependent
variable was not normally distributed then an appropriate
transformation was used. A two-sided p-value less than 0.05 was
considered statistically significant.
Results
All 42 subjects completed at least 6 months of treatment. Five
subjects discontinued treatment after the V2 visit at 6 months due
to drug-related side effects, as detailed below. The remaining 37
subjects continued on treatment for a full year.
Evaluation of safety and tolerability
For the most part, VPA was well tolerated and drug-related side
effects mild. Grade I mood alteration was reported in three
subjects. Grade II weight gain associated with functional decline
led to discontinuation of VPA after V2 (6 months) in 2 subjects
(both 9 year old girls, one with type II, the other with type IIIa but
non-ambulatory). Poor compliance or lack of perceived benefit led
to discontinuation in 3 additional subjects after V2 (2 siblings with
type II, a 5 year old girl and 7 year old boy, and a poorly
compliant 3 year old boy with type II who repeatedly refused oral
dosing). One subject developed grade IV acidosis and carnitine
depletion with respiratory failure requiring intubation and
mechanical ventilation (3 year old type I subject). No deaths
occurred during the study. Mean overnight (minimum 12 hour)
trough VPA levels were 52 mg/dL (V1), 64 mg/dL (V2), and
59 mg/dL (V3). Abnormal laboratory values at baseline and
during treatment are depicted in table 1; grade I elevations in
transaminases without clinical correlate were present at baseline in
3 subjects and in 20 subjects (48%) for at least one visit. Transient
grade I thrombocytopenia occurred in 2 subjects in association
with illness. Grade I anemia was observed in 8 subjects at baseline
and 19 subjects (45%) on treatment. Grade I leukopenia was
frequent (36%) but absolute neutrophil counts remained
.1.0610
3/uL in all subjects. Two subjects had low carnitine
levels at baseline and a substantial proportion of the first thirteen
subjects enrolled demonstrated reductions in total or free plasma
carnitine within the first 3 months of treatment (Figure S2). In two
subjects, this was associated with transient worsening of gross
motor function which reversed with carnitine supplementation.
Our Data Safety and Monitoring Board recommended supple-
mentation of carnitine 50 mg/kg/day in all subjects subsequent to
the first interim safety analysis.
Evaluation of gross motor function
Gross motor function was assessed using the MHFMS in a
subgroup of 27 of 29 non-ambulatory SMA II subjects; one 14.9
year old subject with severe contractures who was no longer able
to sit unsupported, and one uncooperative 2.8 year-old toddler
were not evaluated with the MHFMS. Mean age of the remaining
27 subjects was 4.58 years. All subjects completed V1 and V2 visits
and 25 (86%) completed all three visits. V1 was performed at 3.2
(2.3–4.3) months; V2 at 6.8 (5.5–9.9) months and V3 at 13 (8.7–
15.6) months following treatment initiation. Mean MHFMS scores
improved by 2.15; 2.92; and 4.65 at V1, V2 and V3 visits
respectively, compared to baseline (table 2, p#0.001). Motor
function in type II subjects was then defined as stable, deteriorated
or improved using a three or six point change in the MHFMS
score. Each time point was examined for frequency of that change
from baseline for the entire cohort (table 3, part I). We further
explored the effect of age on change in motor function (table 3,
part II). Of note, 8/16 (50%) children ,5 years of age achieved at
least a 6 point improvement after 1 year, while no children $5
years of age demonstrated a six point improvement. The most
significant change in scores was observed in 5 SMA type II
children ages 25–34 months at enrollment who gained from 8–
15 points. Table 4 further documents the effect of age on change
in motor function for those children who achieved at least a
3 point improvement on the MHFMS.
Gross motor function was assessed using the MHFMS in a
subgroup 10 of 11 ambulatory SMA III subjects. Increase in
MHFMS scores in this cohort was limited by ceiling effects since
several scored maximally at baseline (table 2).
Evaluation of pulmonary function measures
Pulmonary function testing was performed in 14 subjects $5
years of age, comprised of 10 type II subjects and 4 type III
subjects. We observed a significant improvement in MIP values at
the V1 and V2 visits, and in FVC, FEV1 and MIP values at the
V3 visit in type II subjects (table 5).
Table 1. Percent of Subjects With Abnormal Lab Values
Before and During Treatment All Patients (n=42).
Laboratory Parameter Baseline Incidence Treatment Incidence
ALT 7% 19%
AST 10% 38%
WBC 12% 36%
HGB 17% 45%
HCT 17% 48%
Platelets 0% 5%
Neutrophils 36% 57%
ALT=alanine aminotransferase; AST=aspartate aminotransferase; WBC=total
white blood count; HGB=hemoglobin; HCT=hematocrit.
doi:10.1371/journal.pone.0005268.t001
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Total lean body mass was stable but fat mass increased 38%
between the baseline and the one year visit in type II subjects; this
is in contrast to a 14% increase in type III subjects (table 6). We
observed progressive increases in total body bone mineral density
and content (BMD, BMC) across all treatment visits in type II
subjects (p#0.0034) and at V2 and V3 in type III subjects
(p#0.0066). When change in MHFMS score was analyzed by
change in fat mass, those with three or six point gains
demonstrated a lower gain in fat mass than those who were stable
or deteriorated (p=NS; table 7).
Evaluation of electrophysiologic measures of denervation
CMAP amplitude increased over baseline at each visit. The
increase in mean values was significant for V2 and V3 in type II
subjects and for all visits for type III subjects (table 8, p#0.0127).
There was also a significant difference in CMAP values by change
in MHMFS. At V1, subjects showing at least a three point
Table 3. Deterioration vs. Improvement in MHFMS score, SMA type II.
Part I. Three vs. Six point change, All type II Subjects
Criteria Change V1 V2 V3
Three-Point N=27 N=26 N=23
Deterioration 2 (7%) 1 (4%) 1 (4%)
Stable 14 (52%) 12 (46%) 6 (26%)
Improvement 11 (41%) 13 (50%) 16 (70%)
Six-Point
Deterioration 0 0 1 (4%)
Stable 23 (85%) 21 (81%) 14 (61%)
Improvement 4 (15%) 5 (19%) 8 (35%)
Part II. Deterioration vs. Improvement by Age, Six-Point Change
Criteria Change V1 V2 V3
Under 5 years N=18 N=17 N=16
Deterioration 0 0 0
Stable 14 (78%) 12 (71%) 8 (50%)
Improvement 4 (22%) 5 (29%) 8 (50%)
5+ years N=9 N=9 N=7
Deterioration 0 0 1 (14%)
Stable 9 (100%) 9 (100%) 6 (86%)
Improvement 0 0 0
doi:10.1371/journal.pone.0005268.t003
Table 2. Change in MHFMS Score by Time Point.
Time Type II Subjects Type III Subjects
Avg Change Range SD p-value
1 Avg Change Range SD p-value
1
V1 2.15 N=27 25/7 3.02 0.0010 1.0 n=10 22/9 3.20 NS
V2 2.92 N=26 24/13 3.78 0.0006 1.4 n=10 24/11 3.92 NS
V3 4.65 N=23 26/15 4.76 0.0001 1.44 n=9 22/9 3.24 NS
Baseline 13.7 N=27 0/35 8.22 34.4 n=10 10/40 9.40
1P-Values based upon paired t-test.
V1=3 months; V2=6 months; V3=12 months; SD=standard deviation, NS=not significant.
doi:10.1371/journal.pone.0005268.t002
Table 4. Deterioration vs. Improvement by Age: Three-Point
Change, SMA type II.
Criteria Change V1 V2 V3
Under 5 years N=18 N=17 N=16
Deterioration 1 (6%) 0 0
Stable 9 (50%) 6 (35%) 2 (13%)
Improvement 8 (44%) 11 (65%) 14 (87%)
5+ years N=9 N=9 N=7
Deterioration 1 (11%) 1 (11%) 1 (14%)
Stable 5 (56%) 6 (67%) 4 (57%)
Improvement 3 (33%) 2 (22%) 2 (29%)
doi:10.1371/journal.pone.0005268.t004
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best response in those with less severe denervation (table 9;
p=0.03 ). Changes in MUNE negative peak area or amplitude
values were not significant.
Evaluation of SMN2 copy number and quantitative
measures of SMN mRNA in whole blood samples
A linear regression analysis was performed on the transformed
MHFMS scores (square root transformation) to evaluate the
influence of genetic variables, including SMN2 copy number and
SMN mRNA levels on MHFMS (Table 10). The results indicate
no statistically significant relationship between MHFMS score and
SMN mRNA levels, but do indicate a positive relationship
between SMN2 copy number and SMA type with MHFMS
score. Subjects with 3 SMN2 copies had an average of 0.67 flSMN
compared to 0.79 flSMN in subjects with 4 SMN2 copies (Table
S3). D7SMN levels were on average 1.04 and 1.15 for SMN2
copies 3 and 4, respectively. These results indicate no relationship
between SMN mRNA levels and SMN2 copy number. There was
a trend toward an increased relative amount of D7SMN
transcripts per SMA type (0.9160.47 for type 2 vs. 1.4261.11
for type 3; p=0.053). The mean relative amount of flSMN and
D7SMN transcripts was 0.6760.29 and 0.9160.47 for type II and
0.77613 and 1.4261.11 for type III, respectively. Baseline
measures point to the high degree of inter-patient variability in
the relative amount of SMN transcripts, as previously reported
[36,37].
There were no significant changes in the relative amount of
flSMN transcripts in response to drug treatment. There was a
significant decrease in D7SMN transcripts between baseline and
V2 (p=0.0053) and V3 (p=0.0429) for type II subjects (table 11).
Similar results were observed when using PGK1 as endogenous
control to normalize for amount of input cDNA template and RT-
PCR efficiency (baseline data in Table S3, treatment data not
shown). Finally, there was no relationship between decreased
D7SMN transcripts and any physiological or functional measure.
Discussion
In this open label study, we enrolled a relatively heterogeneous
group of SMA subjects, although we focused recruitment
predominantly on children with SMA types II and III. Our
experience emphasizes the need to stratify subjects by SMA type,
age and current gross motor abilities in future trials since the
majority of outcome measures examined in this study were optimal
for only a subset of subjects which was highly dependent on the
Table 5. Change in Pulmonary Function Tests from Baseline by Time Point.
Time Type II Subjects N=10 Type III Subjects N=4
Avg Change Range SD p-value
1 Avg Change Range SD
V1 (3 months)
FVC (L) 0.04 0.10 NS 0.10 0.27
20.06/0.22 20.10/0.41
FEV1 (L) 0.00 0.12 NS 20.03 0.09
20.13/0.22 20.12/0.05
MIP (cm H2O) 211.0 8.9 p=0.0059 25.7 20.0
224.0/1.0 226/14.0
MEP (cm H2O) 18.0 27.9 NS 29.3 23.2
27.0/81.0 235.0/10.0
V2 (6 months)
FVC (L) 0.07 0.12 NS 0.09 0.23
20.12/0.21 20.11/0.40
FEV1 (L) 0.04 0.15 NS 20.03 0.14
20.27/0.22 20.10/0.22
MIP (cm H2O) 216.6 17.4 p=0.0212 213.0 17.0
239.0/20.0 238.0/0.0
MEP (cm H2O) 16.9 24.5 NS 7.25 17.9
24.0/74.0 27.0/30.0
FVC (L) 0.12 0.14 p=0.0472 0.28 0.20
20.12/0.26 20.14/0.42
FEV1 (L) 0.12 0.14 p=0.0467 0.26 0.21
20.12/0.26 20.12/0.41
MIP (cm H2O) 216.6 17.7 p=0.0481 216.6 30.2
235.0/18.0 238.0/4.7
MEP (cm H2O) 14.3 16.9 NS 1.3 23.6
23.0/47.0 215.0/18.0
FVC=forced vital capacity; FEV1=forced expiratory volume in 1 second; MIP=maximal inspiratory pressure; MEP=maximum expiratory pressure.
doi:10.1371/journal.pone.0005268.t005
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fragility.
This study provides evidence that VPA can be used safely in
SMA subjects .2 years of age, as long as carnitine status is closely
monitored. VPA is known to alter enteral absorption, inhibit
biosynthesis and secondarily deplete carnitine from muscle by
direct binding and excretion in the urine [38]. Given the
diminished lean body mass in SMA subjects, an increased
susceptibility to carnitine depletion is not surprising. Decreased
nutritional intake and depleted whole body carnitine stores related
to an associated abnormality in fatty acid metabolism may be
contributing factors [39,40]. Thus, treatment with VPA in the
absence of close monitoring and supplemental carnitine therapy
could increase risks for further muscle weakness or fatal
hepatotoxicity [41]. In this study, we did not observe any serious
clinical or laboratory evidence of hepatotoxicity with careful
monitoring and supplementation but grade I elevations of
transaminases were common. Infants and children less than two
years of age, a group not included in the current study,
theoretically have a greater risk of such complications.
The apparent positive effect of treatment on bone density is
surprising since prolonged VPA treatment has been associated
with decreased bone density in other populations [42–45].
Whether the observed increased bone density is spurious or
relates to increased weight gain, weight bearing or other factors is
unclear. The significant increase in fat mass in the absence of an
increase in lean mass is concerning given the detrimental impact
weight gain could have on gross motor function and potential
long-term consequences for general health. Weight gain was not
uniform across the population; rather, non-ambulatory subjects
$5 years, or those already with such a tendency appear to be at
greatest risk. Notably, children demonstrating the most significant
improvement in gross motor function gained less fat mass
compared to those who displayed stable or deteriorated motor
function.
Maximum CMAP amplitudes showed a statistically significant
increase from baseline, while MUNE values did not change. This
would imply that axonal reinnervation did not account for the
change, but that the observed changes may be due to
reinnervation of muscle via ‘‘sprouting’’ from remaining motor
units or a direct trophic effect on muscle. If future controlled trials
confirm that increased CMAP amplitude is a consistent marker of
Table 6. Change in Lean and Fat Mass and Bone Density by Time Point.
Time Type II Subjects N=29 Type III Subjects N=10
Avg Change
1 SD p-value
2 Avg Change
1 SD p-value
2
V1 (3 months)
Lean mass, grams 123 973 NS 2267 1865 NS
Fat mass, grams 1094 1034 0.0003 1269 1844 0.078
Total BMD, g/cm
2 0.05 0.06 0.0003 0.02 0.05 NS
Total BMC, grams 33.6 54.4 0.0036 71.0 80.0 0.0287
V2 (6 months)
Lean mass, grams 2366 1174 NS 184 1582 NS
Fat mass, grams 2579 2013 ,0.0001 2101 2213 0.0149
Total BMD, g/cm
2 0.05 0.06 ,0.0001 0.03 0.03 0.0066
Total BMC, grams 99.5 68.1 ,0.0001 90.5 76.2 0.0045
V3 (12 months)
Lean mass, grams 2212 1029 NS 322 960 NS
Fat mass, grams 3680 2470 ,0.0001 2596 3193 0.0406
Total BMD g/cm
2 0.07 0.06 ,0.0001 0.07 0.04 0.0011
Total BMC, grams 145 66.4 ,0.0001 124.2 98.1 0.0052
1Range at baseline in Table S1.
2P-values based upon paired t-test.
BMD=bone mineral density; BMC=bone mineral content; g/cm
2=grams/centimeter squared; SD=standard deviation, NS=not significant.
doi:10.1371/journal.pone.0005268.t006
Table 7. Change in MHFMS Score by Change in Fat Mass.
Criteria Change V1 V2 V3
Three-Point
Deterioration 2320 7541 9502
N=2 N=1 N=1
Stable 1173 1995 4459
N=14 N=12 N=6
Improvement 825 2318 2918
N=11 N=13 N=16
P-value
1 0.73 0.22 0.09
Six-Point
Deterioration 9502.0
N=0 N=0 N=1
Stable 1287 2584 3624
N=23 N=21 N=1
Improvement 189 1460 2839
N=4 N=5 N=8
P-value
1 0.10 0.27 0.18
1P-value based upon ANOVA.
doi:10.1371/journal.pone.0005268.t007
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function, then this outcome measure could prove a powerful
surrogate biomarker for future clinical trials.
Changes in pulmonary function were observed; however, the
significance is limited by the small number of subjects $5 years in
each cohort. Nonetheless, PFT measures are important with
regard to clinical outcomes in patients with SMA, so other means
of reliably determining pulmonary function in younger children is
an important goal.
We had hypothesized that VPA might increase flSMN and
D7SMN mRNA levels in blood samples in light of prior data
demonstrating increased mRNA and protein levels in patient-derived
cells [16–20]. When analyzed as a group, we observed a significant
decrease in the relative amount of D7SMN mRNA in SMA type II
subjects while flSMN transcripts were unchanged. However, flSMN
and D7SMN mRNA levels fluctuated throughout drug treatment,
with patients showing increased, decreased or unaltered relative
amounts of both transcripts. This variability contrasts with the fairly
stable SMN mRNA levels observed in untreated patients [21,36,37].
Consistent with previously published data, these results are suggestive
of a VPA response and SMN mRNA could help discriminate
between non-responders and responders [21]. Furthermore, the
implication of decreased relative D7SMN mRNA levels in the
absence of changes in flSMN would be to increase the ratio of flSMN
to SMND7, the major discriminator between SMA subjects and
unaffected controls/carriers when using relative measures of SMN
mRNA, suggesting that these changes could be important. Finally, in
order for SMN mRNA levels in blood to inform us about VPA effects
in spinal cord, there must be a significant relationship between SMN
mRNA and a clinical outcome measure. We did not observe any
relationship between changes in D7SMN and any of the outcome
measures in this pilot open label study. One reason for this may be
that blood may not be the appropriate tissue to screen for biomarkers
of SMA. Alternatively, extensive variability in SMN mRNA levels
during treatment trials may mask significant relationships in a sub-set
of SMA patients. Fluctuations in SMN mRNA levels may be
amplified by fluctuations in transcript levels produced by endogenous
controlsusednormalizefortheamountofinput templateandefficacy
of RT-PCR. VPA is a non-specific drug target and may itself affect
expression of genes used as endogenous controls. Weobserved similar
Table 8. Change in Maximum Ulnar CMAP Amplitude and MUNE Negative Peak Area from Baseline by Time Point.
Time Type II Subjects (n=29) Type III Subjects (n=10)
Avg Change Range SD p-value
1 Avg Change Range SD p-value
1
V1 (3 months)
CMAP (mV) 0.12 20.98/1.26 0.38 0.0909 1.03 20.10/2.50 0.95 0.0074
MUNE (mVms) 23.03 295.0/10.0 18.6 NS 20.50 238.0/53.0 28.2 NS
V2 (6 months)
CMAP (mV) 0.23 20.96/1.12 0.39 0.0041 1.20 0.23/3.56 1.13 0.0085
MUNE (mVms) 25.59 2117.0/7.0 22.2 NS 216.4 293.0/17.0 33.8 NS
V3 (12 months)
CMAP (mV) 0.35 20.52/1.58 0.54 0.0031 1.44 20.24/3.75 1.35 0.0127
MUNE (mVms) 28.58 2126.0/10.0 26.3 NS 217.7 293.0/17.0 51.0 NS
1P-values based upon paired t-test.
SD=standard deviation, NS=not significant.
doi:10.1371/journal.pone.0005268.t008
Table 9. Average Maximum Ulnar CMAP vs. Three-point and
Six-point Change in MHFMS Score.
Criteria Change CMAP (mV) CMAP (mV) CMAP (mV)
V1 V2 V3
3-Point
Deterioration 0.46 0.47 0.55
N=2 N=1 N=1
Stable 1.59 1.70 1.22
N=14 N=12 N=6
Improvement 2.05 2.11 2.00
N=11 N=13 N=16
P-value
1 0.03 0.07 0.29
6-Point
Deterioration 0.55
N=0 N=0 N=1
Stable 1.52 1.68 1.33
N=23 N=21 N=14
Improvement 2.67 2.58 2.61
N=4 N=5 N=8
P-value
1 0.29 0.24 0.24
1P-value based upon ANOVA.
Maximum ulnar CMAP (compound muscle action potential amplitude).
doi:10.1371/journal.pone.0005268.t009
Table 10. Linear Regression of Square Root of MHFMS Total
Score Versus Genetic Variables.
Term Estimate Std Error t Ratio Prob.|t|
Intercept 20.77 1.07 20.71 0.4818
flSMN 20.19 0.82 20.23 0.8177
D7SMN 20.68 0.45 21.50 0.1455
SMN2 0.52 0.25 2.05 0.0497
Type 2.35 0.48 4.93 ,.0001
doi:10.1371/journal.pone.0005268.t010
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not have any evidenceto suggest that these genes areaffected by VPA
treatment. Nonetheless, there is a need for an absolute quantification
method to measure SMN mRNA in order to remove variability
introduced by the use of endogenous controls to normalize data.
In conclusion, this study provides good evidence that VPA can
be used safely in SMA subjects over 2 years of age in the setting of
close monitoring of carnitine status. This being said, further studies
of VPA in infants and young children are needed to better assess
safety in this more vulnerable cohort. This study provides evidence
in support of improvement in gross motor function in younger
non-ambulatory type II children. This finding was unexpected and
it is unclear whether this improvement reflects a therapeutic drug
effect, maturation or increased cooperation on improved scores in
the youngest subjects. These data suggest that further studies with
VPA are warranted, although clearly such findings must be
replicated in randomized, controlled efficacy studies. The data
presented here emphasizes the benefit of a trial design with a less
heterogenous population of younger SMA subjects, particularly in
light of significantly increased fat mass and lack of apparent benefit
of VPA treatment in older non-ambulatory subjects. Furthermore,
our experience indicates that the MHFMS scale alone is not
adequate to measure motor function in ambulatory SMA subjects,
prompting us to explore other measures to assess functional
change in this population. Future clinical trials targeted to this
cohort should generate additional informative data as to the
usefulness of PFTs, timed test modules, and biomarker data
including electrophysiologic measures of denervation, which
appear to have promise in this cohort.
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